Asset Details
Do you wish to reserve the book?
Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging
Do you wish to request the book?
Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging
2020
Overview
: Optimal intratumor distribution of an anticancer drug is fundamental to reach an active concentration in neoplastic cells, ensuring the therapeutic effect. Determination of drug concentration in tumor homogenates by LC-MS/MS gives important information about this issue but the spatial information gets lost. Targeted mass spectrometry imaging (MSI) has great potential to visualize drug distribution in the different areas of tumor sections, with good spatial resolution and superior specificity. MSI is rapidly evolving as a quantitative technique to measure the absolute drug concentration in each single pixel.
: Different inorganic nanoparticles were tested as matrices to visualize the PARP inhibitors (PARPi) niraparib and olaparib. Normalization by deuterated internal standard and a custom preprocessing pipeline were applied to achieve a reliable single pixel quantification of the two drugs in human ovarian tumors from treated mice.
: A quantitative method to visualize niraparib and olaparib in tumor tissue of treated mice was set up and validated regarding precision, accuracy, linearity, repeatability and limit of detection. The different tumor penetration of the two drugs was visualized by MSI and confirmed by LC-MS/MS, indicating the homogeneous distribution and higher tumor exposure reached by niraparib compared to olaparib. On the other hand, niraparib distribution was heterogeneous in an ovarian tumor model overexpressing the multidrug resistance protein P-gp, a possible cause of resistance to PARPi.
: The current work highlights for the first time quantitative distribution of PAPRi in tumor tissue. The different tumor distribution of niraparib and olaparib could have important clinical implications. These data confirm the validity of MSI for spatial quantitative measurement of drug distribution providing fundamental information for pharmacokinetic studies, drug discovery and the study of resistance mechanisms.
Publisher
Ivyspring International Publisher Pty Ltd,Ivyspring International Publisher
Subject
/ Animals
/ Antineoplastic Agents - pharmacokinetics
/ Drugs
/ Ethanol
/ Female
/ Indazoles - pharmacokinetics
/ Ions
/ Mice
/ Ovarian Neoplasms - drug therapy
/ Phthalazines - pharmacokinetics
/ Piperazines - pharmacokinetics
/ Piperidines - pharmacokinetics
/ Pixels
/ Poly(ADP-ribose) Polymerase Inhibitors - pharmacology
/ Tumors
